MADRIGAL PHARMACEUTICALS, INC. Repayments of Secured Debt
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Repayments of Secured Debt of $121.66 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2025-12-31 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2024-12-31 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2016-06-30 was $2.29M, a 0.61% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2016-03-31 was $2.31M, a 0.30% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2025 was $121.66M.
- MADRIGAL PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2024 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2023 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2015 was $9.21M, a 2.50% decline from fiscal 2014.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $121.66M 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $121.66M 10-Q · filed 2025-11-04 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2016-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | $4.60M 10-Q · filed 2016-07-20 | $6.90M derived: sum of 3 quarters · filed 2016-07-20 | $9.21M derived: sum of 4 quarters · filed 2016-07-20 |
| 2016-03-31 | $2.31M 10-Q · filed 2016-05-10 | $4.61M derived: sum of 2 quarters · filed 2016-05-10 | $6.92M derived: sum of 3 quarters · filed 2016-05-10 | $9.22M derived: sum of 4 quarters · filed 2016-07-20 |
| 2015-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $4.61M derived: sum of 2 quarters · filed 2016-03-15 | $6.91M derived: sum of 3 quarters · filed 2016-07-20 | $9.21M 10-K · filed 2016-03-15 |
| 2015-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $4.61M derived: sum of 2 quarters · filed 2016-07-20 | $6.91M 10-Q · filed 2015-11-05 | $9.21M derived: sum of 4 quarters · filed 2016-07-20 |
| 2015-06-30 | $2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | $4.60M 10-Q · filed 2016-07-20 | $6.90M derived: sum of 3 quarters · filed 2016-07-20 | $9.20M derived: sum of 4 quarters · filed 2016-07-20 |
| 2015-03-31 | $2.30M 10-Q · filed 2016-05-10 | $4.60M derived: sum of 2 quarters · filed 2016-05-10 | $6.90M derived: sum of 3 quarters · filed 2016-05-10 | $9.26M derived: sum of 4 quarters · filed 2016-05-10 |
| 2014-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $4.60M derived: sum of 2 quarters · filed 2016-03-15 | $6.96M derived: sum of 3 quarters · filed 2016-03-15 | $9.45M 10-K · filed 2016-03-15 |
| 2014-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $4.66M derived: sum of 2 quarters · filed 2015-11-05 | $7.15M 10-Q · filed 2015-11-05 | $7.38M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | $2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $4.85M 10-Q · filed 2015-08-06 | $5.09M derived: sum of 3 quarters · filed 2016-03-15 | $5.31M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | $2.49M 10-Q · filed 2015-05-07 | $2.72M derived: sum of 2 quarters · filed 2016-03-15 | $2.94M derived: sum of 3 quarters · filed 2016-03-15 | $3.13M derived: sum of 4 quarters · filed 2016-03-15 |
| 2013-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $452.00K derived: sum of 2 quarters · filed 2016-03-15 | $645.00K derived: sum of 3 quarters · filed 2016-03-15 | $2.62M 10-K · filed 2016-03-15 |
| 2013-09-30 | $218.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $411.00K derived: sum of 2 quarters · filed 2014-11-06 | $2.38M 10-Q · filed 2014-11-06 | $4.35M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $2.17M 10-Q · filed 2014-08-06 | $4.13M derived: sum of 3 quarters · filed 2015-03-12 | $6.09M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $1.97M 10-Q · filed 2014-05-08 | $3.94M derived: sum of 2 quarters · filed 2015-03-12 | $5.90M derived: sum of 3 quarters · filed 2015-03-12 | $6.05M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $3.93M derived: sum of 2 quarters · filed 2015-03-12 | $4.08M derived: sum of 3 quarters · filed 2015-03-12 | $4.23M 10-K · filed 2015-03-12 |
| 2012-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-04 | $2.12M derived: sum of 2 quarters · filed 2013-11-04 | $2.27M 10-Q · filed 2013-11-04 | $2.41M derived: sum of 4 quarters · filed 2014-03-11 |
| 2012-06-30 | $155.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $306.00K 10-Q · filed 2013-08-01 | $451.00K derived: sum of 3 quarters · filed 2014-03-11 | $592.00K derived: sum of 4 quarters · filed 2014-03-11 |
| 2012-03-31 | $151.00K 10-Q · filed 2013-04-30 | $296.00K derived: sum of 2 quarters · filed 2014-03-11 | $437.00K derived: sum of 3 quarters · filed 2014-03-11 | |
| 2011-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $286.00K derived: sum of 2 quarters · filed 2014-03-11 | $378.00K 10-K · filed 2014-03-11 | |
| 2011-09-30 | $141.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $233.00K 10-Q · filed 2012-11-06 | ||
| 2011-06-30 | $92.00K 10-Q · filed 2012-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |